A new type of therapy drug that has been shown to decrease the need for hospitalizations and emergency department visits in COVID-19 patients is now available in Minnesota.
The U.S. Department of Health and Human Services (HHS) has started distribution of bamlanivimab, a new drug for treating mild and moderate COVID-19 cases in Minnesota.
HHS secured a limited supply of this antibody treatment and is expected to continue weekly shipments to health care facilities at least through the end of 2020.
Only children and adults who are at high risk for severe disease will be eligible, and those conditions are listed in the Food and Drug Administration’s Emergency Use Authorization (PDF), which is posted on the MDH website.
